Tachycardia is defined as:
Question 1/10
An arrhythmia with a rate greater than 150/min
An arrhythmia with a rate greater than 100/min
Any rhythm disorder with a heart rate less than 60/min
An organized rhythm without a pulse
Synchronized cardioversion is recommended for:
Question 2/10
Monomorphic VT in a stable patient
Pulseless rhythms
Unstable SVT
Polymorphic VT
What is the correct energy dose for unstable atrial fibrillation when delivering monophasic synchronized shocks?
Question 3/10
50 to 100 J
100 J
Treat with high-energy shocks (defibrillation doses)
200 J
AV nodal blocking agents should be avoided in:
Question 4/10
Patients with a regular SVT
Patients with a regular VT
Patients with an irregular wide-complex tachycardia
All of the above
Which drug is the preferred intervention for terminating narrow-complex tachycardias that are symptomatic (but stable) and supraventricular in origin (SVT)?
Question 5/10
Epinephrine
Amiodarone
Atropine
Adenosine
Adenosine should not be given to:
Question 6/10
Patients with asthma
Pregnant women
Patients with SVT
Patients with a narrow QRS with regular rhythm
If SVT does not respond to vagal maneuvers, how much adenosine do you give:
Question 7/10
20mL rapid IV push
12 mg rapid IV push
6 mg IV push over 10 seconds
6mg rapid IV push over 1 second
Which of the following statements is not true?
Question 8/10
Sinus tachycardia is a heart rate that is greater than 100/min and is generated by sinus node discharge
Sinus tachycardia is caused by cardiac conditions
In sinus tachycardia, the goal is to identify and treat the underlying systemic cause.
Cardioversion is contraindicated in Sinus Tachycardia
Vagal maneuvers alone will terminate about what percentage of SVTs?
Question 9/10
25%
90%
75%
50%
End points for the administration of procainamide include:
Question 10/10
Hypotension
Duration of QRS increases by 25%
Maximum dose of 7 mg/kg is reached
Increase in heart rate by 30 points
